Xbrane’s Ranibizumab Marches On With US FDA Filing Imminent

Swedish Firm Reveals Further Phase III Data For Proposed Lucentis Biosimilar

 
• By Dean Rudge
  
Eye
Xbrane is chasing approvals like the ones held by Samsung Bioepis • Source: Shutterstock

More from Products

More from Generics Bulletin